|
| Catalog Number | Size | Price (USD) | Shopping Cart |
|---|---|---|---|
| PR27023-2 | 2 ug | $85.00 | Buy Now | Add to Cart |
| PR27023-10 | 10 ug | $195.00 | Buy Now | Add to Cart |
![Picture[2]](/site/special/A8x764ex66x1.jpg)
BMP-2 belongs to the Bone-growth regulatory factors that are members of the transforming growth factor-beta (TGF-beta) superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.
Images: At 45 days, the bone mineralization rates of the (A) rhBMP-2/CPC and the (B) rhBMP-2/GM/CPC groups were greater than those of the (C) untreated group, and the rates of the rhBMP-2/GM/CPC group were greater than those of the rhBMP-2/CPC group. However, there were no differences in the mineralization rates among the (D) rhBMP-2/CPC, (E) rhBMP-2/GM/CPC, and (F) untreated groups at 140 days (Double fluorescent labeling; original magnification, ×100). Clinical Orthopaedics and Related Research® © The Association of Bone and Joint Surgeons® 2010 10.1007/s11999-010-1321-9
BMP-2: Customer Publications
More Links:
References:
1. Effect of recombinant human bone morphogenetic protein-2 on mandibular distraction at different rates in a rabbit model. Tissue Eng 2006 Nov;12(11):3181-8
2. Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 2007 Feb;13(2):293-300
3. The in vivo biological effects of intradiscal recombinant human bone morphogenetic protein-2 on the injured intervertebral disc: an animal experiment. Spine 2007 May 15;32(11):1174-80
4. The effect of recombinant human bone morphogenetic protein-2 on the osteogenic potential of rat mesenchymal stem cells after several passages. Acta Orthop 2007 Apr;78(2):285-92
5. Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 2007 May;121(1):94-104
6. Re: Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006; 31:2534-40. Spine 2007 Mar 15;32(6):708; author reply 708








